Background:

Pancuronium Dibromide is a bis-quaternary steroid that is a competitive nicotinic antagonist.Target: nAChRPancuronium Dibromide is a competitive AChR antagonist (IC50 = 5.5 nM) and acts as a skeletal muscle relaxant. Pancuronium Dibromide interrupts neuromuscular transmission by competing with acetylcholine for receptor sites on the motor end-plate. Pancuronium dibromide is a non-depolarizing agent. Pancuronium is a typical non-depolarizing curare-mimetic muscle relaxant. It acts as a competitive acetylcholine antagonist on neuromuscular junctions, displacing acetylcholine (hence competitive) from its post-synaptic nicotinic acetylcholine receptors. It is (unlike suxamethonium) a non-depolarizing agent, which means that it causes no spontaneous depolarizations upon association with the nicotinic receptor in neuromuscular junction, thus producing no muscle fasciculations upon administration [1-3].

参考文献:
[1]. Fryer, A.D. and J. Maclagan, Pancuronium and gallamine are antagonists for pre- and post-junctional muscarinic receptors in the guinea-pig lung. Naunyn Schmiedebergs Arch Pharmacol, 1987. 335(4): p. 367-71.
[2]. Maestrone, E., et al., Extracellular pancuronium affects sodium current in chick embryo sensory neurones. Br J Pharmacol, 1994. 111(1): p. 283-7.
[3]. Lowenick, C.V., et al., Open channel and competitive block of nicotinic receptors by pancuronium and atracurium. Eur J Pharmacol, 2001. 413(1): p. 31-5.